A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2027

Conditions
Endometrial Adenocarcinoma
Interventions
DRUG

ACR-368

ACR-368 is an experimental drug

DRUG

Gemcitabine

Sensitization of tumor cells is provided through administration of ULDG

DIAGNOSTIC_TEST

OncoSignature

Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy

Trial Locations (69)

10016

RECRUITING

Laura & Isaac Perlmutter Cancer Center, New York

10032

RECRUITING

New York Presbyterian Hospital-Columbia University Medical Center, New York

10065

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

10128

RECRUITING

Mount Sinai Health System, New York

14642

RECRUITING

University of Rochester Medical Center, Rochester

15224

RECRUITING

West Penn Hospital, Pittsburgh

19111

ACTIVE_NOT_RECRUITING

Fox Chase Cancer Center, Philadelphia

20817

COMPLETED

American Oncology Partners of Maryland PA, Bethesda

20892

RECRUITING

National Institutes of Health, Clinical Center, Bethesda

20910

COMPLETED

Holy Cross Hospital, Silver Spring

22903

RECRUITING

University of Virginia Health System, Charlottesville

23298

RECRUITING

Virginia Commonwealth University, Richmond

27599

COMPLETED

University of North Carolina at Chapel Hill, Chapel Hill

28374

RECRUITING

FirstHealth of the Carolinas, Pinehurst

30322

RECRUITING

Emory University, Atlanta

30501

COMPLETED

Northeast Georgia Medical Center, Gainesville

33140

RECRUITING

Mount Sinai Comprehensive Cancer Center, Miami Beach

33905

RECRUITING

Florida Gynecologic Oncology/Regional Cancer Center, Fort Myers

36604

COMPLETED

University of South Alabama Mitchell Cancer Institute, Mobile

43026

RECRUITING

Ohio State University, Hilliard

44195

COMPLETED

Cleveland Clinic Foundation, Cleveland

44718

COMPLETED

Gabrail Cancer Center, Canton

45267

RECRUITING

University of Cincinnati Cancer Center, Cincinnati

45459

RECRUITING

Miami Valley Hospital South, Centerville

46260

RECRUITING

Ascension St. Vicent Hospital, Inc., Indianapolis

48201

RECRUITING

Karmanos Cancer Institute, Detroit

52252

RECRUITING

University of Iowa, Iowa City

53226

RECRUITING

Froedtert and Medical College of Wisconsin, Milwaukee

57104

RECRUITING

Sanford Health, Sioux Falls

60611

RECRUITING

Northwestern Medicine, Chicago

60612

RECRUITING

University of Illinois Cancer Center, Chicago

60637

RECRUITING

University of Chicago Medicine, Chicago

61801

RECRUITING

Carle Cancer Center, Urbana

64132

RECRUITING

HCA Midwest, Kansas City

70112

RECRUITING

LSU Health Sciences, New Orleans

71103

RECRUITING

Trials365, LLC, Shreveport

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

73104

RECRUITING

Stephenson Cancer Center at OU Health, Oklahoma City

75231

COMPLETED

Texas Oncology-Dallas Presbyterian Hospital, Dallas

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

76104

COMPLETED

Texas Oncology, Fort Worth

77030

RECRUITING

University of Texas, MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado, Aurora

84112

RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

85016

RECRUITING

HonorHealth, Phoenix

85711

RECRUITING

Arizona Oncology Associate, PC- HOPE, Tucson

90033

COMPLETED

USC/Norris Comprehensive Cancer Center, Los Angeles

90048

RECRUITING

Cedars Sinai Medical Center, Los Angeles

90404

RECRUITING

University of California Los Angeles (UCLA), Santa Monica

91010

RECRUITING

City of Hope National Medical Center, Duarte

92037

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

92663

RECRUITING

Hoag Cancer Center, Newport Beach

92868

ACTIVE_NOT_RECRUITING

UC Irvine Health, Orange

94304

RECRUITING

Stanford Cancer Center, Palo Alto

95817

RECRUITING

University of California, Davis Comprehensive Cancer Center, Sacramento

97239

ACTIVE_NOT_RECRUITING

Oregon Health & Sciences University, Portland

97401

ACTIVE_NOT_RECRUITING

Oncology Associates of Oregon, Eugene

98104

RECRUITING

Swedish Cancer Center, Seattle

98109

COMPLETED

Fred Hutchinson Cancer Center, Seattle

98684

COMPLETED

Northwest Cancer Specialists, P.C., Vancouver

99204

RECRUITING

Providence Sacred Heart Medical Center and Children's Hospital, Spokane

99208

COMPLETED

Summit Cancer Center, Spokane

99508

COMPLETED

Alaska Women's Cancer Center, Anchorage

06520

COMPLETED

Yale Cancer Center, New Haven

02115

RECRUITING

Dana Farber Cancer Institute, Boston

01605

RECRUITING

University of Massachusetts Chan Medical School, Worcester

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

08903

RECRUITING

Rutgers Cancer Institute of NJ, New Brunswick

02905

RECRUITING

Women & Infants Hospital, Providence

Sponsors
All Listed Sponsors
collaborator

GOG Foundation

NETWORK

lead

Acrivon Therapeutics

INDUSTRY

NCT05548296 - A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Biotech Hunter | Biotech Hunter